Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Short Interest Update

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) was the target of a large decline in short interest in the month of August. As of August 31st, there was short interest totaling 272,812 shares, a decline of 53.3% from the August 15th total of 584,609 shares. Approximately 4.2% of the company’s shares are short sold. Based on an average daily volume of 1,219,586 shares, the short-interest ratio is currently 0.2 days.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on CELZ shares. Wall Street Zen raised shares of Creative Medical Technology from a “sell” rating to a “hold” rating in a research note on Saturday. Roth Capital reissued a “buy” rating on shares of Creative Medical Technology in a research report on Thursday, August 20th. Finally, Weiss Ratings raised Creative Medical Technology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Creative Medical Technology currently has an average rating of “Hold”.

Creative Medical Technology Price Performance

NASDAQ CELZ opened at $0.96 on Monday. Creative Medical Technology has a 52 week low of $0.62 and a 52 week high of $6.25. The firm has a market capitalization of $6.33 million, a P/E ratio of -0.46 and a beta of 2.04. The company has a 50-day moving average price of $1.01 and a 200-day moving average price of $1.68.

Creative Medical Technology (NASDAQ:CELZ) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02). As a group, equities research analysts anticipate that Creative Medical Technology will post -1.18 EPS for the current year.

Hedge Funds Weigh In On Creative Medical Technology

An institutional investor recently bought a new position in Creative Medical Technology stock. Jane Street Group LLC purchased a new position in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned approximately 1.17% of Creative Medical Technology at the end of the most recent quarter. Hedge funds and other institutional investors own 1.42% of the company’s stock.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.